Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- All Sawai MRs to Use iPads, First for Generics Maker
October 5, 2012
- Data Acquisition Completed for Anti-HIV Treatment, Submission for Regulatory Approval in US, Europe Planned By Year End: Shionogi
October 5, 2012
- Novartis to See Tasigna Sales More than Double, Value of Glivec Maximized
October 5, 2012
- Kyowa Kirin Files for Approval Based on Public Knowledge for IM Administration and Dosage for Leunase
October 5, 2012
- Ono Conducts Nation’s First Microdosing Study for New Drug Candidate
October 5, 2012
- Bayer Files for Fosrenol for Patients with CKD in Preservation Period
October 5, 2012
- MTPC Outsources All Logistics Operations
October 5, 2012
- Takeda, Lundbeck File NDA for Major Depressive Disorder Treatment Vortioxetine in US
October 4, 2012
- Baxter Files for Approval in Japan for Cell Culture Influenza Vaccine
October 4, 2012
- Takeda Initiates Drug Discovery Collaboration with Advinus of India to Boost Research Productivity
October 4, 2012
- Daiichi Sankyo Discontinues PIII Study of ARQ197 in Patients with NSCLC
October 4, 2012
- Sanofi Takes Over 3 Genzyme Products
October 3, 2012
- Astellas Strikes Deal to License JAK Inhibitor to Janssen Biotech Outside Japan
October 3, 2012
- Seikagaku Completes New Production Facilities for Gel-One to Meet Increasing Demand in US
October 3, 2012
- Shionogi Acquires Worldwide Rights for Cholesterol Absorption Inhibitor from Kotobuki
October 3, 2012
- “Comprehensive Strengths” Have Been Biggest Result of Alliance with Roche: Chairman Nagayama of Chugai
October 3, 2012
- Takeda Receives Approval for Hyperlipidemia Drug Lotriga
October 2, 2012
- Bayer Yakuhin Obtains Approval for VEGF Inhibitor Eylea, Santen to Distribute Product
October 2, 2012
- Sanwa Kagaku, Kowa Obtain Approval for DPP-4 Inhibitor Suiny, to Market Under One Brand Name
October 2, 2012
- Qol Reaches Agreement for Approximately Half of Its Price Negotiations with Wholesalers
October 1, 2012
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…